Source: Arch Internal Med
Area: News
This retrospective study, using The Health Improvement Network (THIN) database, evaluated the short and long-term risks of developing diabetic macular oedema (DMO) among patients with type 2 diabetes who were treated with thiazolidinediones (rosiglitazone and pioglitazone).
Researchers identified adult patients with type 2 diabetes (not requiring insulin therapy within 6 months of diagnosis), were 18 years or older, and were registered with the medical practices for at least one year from the index date of January 2000. The THIN database also determined the use of prescribed thiazolidinediones prior to the diagnosis of DMO or prior to censuring of patients with no diagnosis of DME. The primary outcome measure of the study was a new diagnosis of DMO as indicated by READ codes.
The following results were reported:
. A total of 103,368 patients met the inclusion criteria.
. At 1 year, the incidence of DMO was 1.3% (n = ...
Uncategorized